2 terminated, 1 completed, 1 suspended, 1 withdrawn. 5 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Terminated 2, Completed 1, Suspended 1, Withdrawn 1 |
| Phase 2 | 1 | Suspended 1 |
Follow Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified: new trials by email Literature Review of Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified trials Research Report on Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma Vevoctadekin, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 / Phase 2 | Suspended | Fred Hutchinson Cancer Center | 33 | 2025-12-27 | 2026-09-11 |
| Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2023-04-01 | 2023-01-13 | |
| NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Cyclophosphamide, Fludarabine, Lisocabtagene Maraleucel - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 | Completed | Fred Hutchinson Cancer Center | 27 | 2022-12-08 | 2026-09-21 |
| CD19-Specific T Cells Post AlloSCT Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells, Cyclophosphamide, Fludarabine - B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A Rearranged, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | Terminated | M.D. Anderson Cancer Center | 4 | 2020-06-26 | 2021-06-02 |
| huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes, Cyclophosphamide, Fludarabine - Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 | Terminated | Fred Hutchinson Cancer Center | 55 | 2017-11-03 | 2024-04-10 |
Lymphoma, Large B-Cell, Diffuse (5) · Burkitt Lymphoma (2) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, B-Cell (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Hemic and Lymphatic Diseases (5) · Immune System Diseases (5) · Immunoproliferative Disorders (5) · Lymphatic Diseases (5) · Lymphoma (5) · Lymphoproliferative Disorders (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Lymphoma, B-Cell (4) · Lymphoma, Non-Hodgkin (4) · DNA Virus Infections (2) · Epstein-Barr Virus Infections (2) · Hematologic Diseases (2) · Herpesviridae Infections (2) · Infections (2)
Cyclophosphamide (3) · fludarabine (3) · Biopsy (2) · Leukapheresis (2) · Magnetic Resonance Spectroscopy (2) · Phantoms, Imaging (2) · Spinal Puncture (2) · X-Rays (2) · Carmustine (1) · Cytarabine (1) · Etoposide (1) · Melphalan (1) · NKTR-255 (1) · Stem Cell Transplantation (1) · loncastuximab tesirine (1)
Fred Hutchinson Cancer Center (4) · M.D. Anderson Cancer Center (1)
United States (5)
Alexandre Hirayama (1) · Alexandre V. Hirayama, MD (1) · Jordan Gauthier (1) · Partow Kebriaei (1) · Victor Chow (1)